Rani Therapeutics Holdings, Inc. (RANI) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
RANI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RANI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -5186.2% | -2920.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | -1899.1% | -306.6% |
| 2020 | 100.0% | -3581.0% | -3615.4% |
Download Data
Export RANI earnings history in CSV or JSON format
Free sign-in required to download data
Rani Therapeutics Holdings, Inc. (RANI) Earnings Overview
As of May 8, 2026, Rani Therapeutics Holdings, Inc. (RANI) reported trailing twelve-month net income of -$28M, reflecting +21.1% year-over-year growth. The company earned $-0.77 per diluted share over the past four quarters, with a net profit margin of -2920.0%.
Looking at the long-term picture, RANI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2021.
Rani Therapeutics Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including LNTH ($279M net income, 15.2% margin), NUVL (-$450M net income), ARQT (-$2M net income, -4.3% margin), RANI has room to improve margins relative to the peer group. Compare RANI vs LNTH →
RANI Earnings vs Peers
Earnings metrics vs comparable public companies
RANI Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$30M | +11.6% | -$53M | $-1.05 | -2920.0% | -5186.2% |
| 2023 | -$34M | -11.1% | -$66M | $-1.33 | - | - |
| 2022 | -$31M | -267.2% | -$63M | $-1.28 | - | - |
| 2021 | -$8M | +50.1% | -$52M | $-0.42 | -306.6% | -1899.1% |
| 2020 | -$17M | +37.2% | -$17M | $-0.85 | -3615.4% | -3581.0% |
| 2019 | -$27M | - | -$27M | $-1.35 | -2716.8% | -2764.6% |
See RANI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RANI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RANI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRANI — Frequently Asked Questions
Quick answers to the most common questions about buying RANI stock.
Is RANI growing earnings?
RANI EPS is $-0.77, with earnings growth accelerating to +21.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-28M.
What are RANI's profit margins?
Rani Therapeutics Holdings, Inc. net margin is -2920.0%, with operating margin at -5186.2%. Below-average margins reflect competitive or cost pressures.
How consistent are RANI's earnings?
RANI earnings data spans 2019-2024. The accelerating earnings trend is +21.1% YoY. Historical data enables comparison across business cycles.